病毒性結膜炎治療市場：依藥物類別、病毒類型、通路和地區分類

預計到 2026 年，病毒性結膜炎治療市場規模將達到 3.949 億美元，到 2033 年將達到 5.668 億美元。預計從 2026 年到 2033 年，該市場將以 5.3% 的複合年成長率成長。

病毒性結膜炎是由多種病毒引起的急性結膜感染疾病，包括腺病毒和單純皰疹病毒。病毒性結膜炎佔感染性結膜炎病例的絕大多數，高達75%。病毒性結膜炎的特徵性症狀包括眼紅、血管擴張、眼分泌物增加、疼痛和畏光。由一組腺病毒引起的病毒性結膜炎稱為流行性角結膜炎（EKC）。此腺病毒家族包含不同的血清型，可引起咽結膜熱和非特異性濾泡性結膜炎。根據美國眼科學會2018年發表的論文，腺病毒性結膜炎是成人最常見的眼部感染疾病。腺病毒性結膜炎具有高度傳染性，因為引起感染的病毒可以在廚房檯面和類似表面上存活數週。

市場動態

市場參與者正在進行臨床試驗，以開發更有效的腺病毒性結膜炎治療方法，預計在預測期內將推動市場成長。例如，2017年，武田藥品工業株式會社的子公司Shire Plc啟動了臨床試驗，以檢驗其候選藥物SHP640治療成人和兒童腺病毒性結膜炎的安全性和有效性。

市場相關人員正致力於推出新產品，以期鞏固其在全球市場的地位。例如，2018年，艾伯維（AbbVie）旗下子公司艾爾建（Allergan）推出了一款新的非處方人工淚液－「REFRESH REPAIR潤滑眼藥水」。本產品含有羧甲基纖維素（CMC）、透明質酸（HA，惰性成分）和滲透保護劑，旨在保護眼睛免受結膜炎症狀（如乾眼症）的有害影響。

市場參與企業正透過與其他公司建立合作關係來拓展其全球企業發展，從而加強其分銷網路，預計這將推動病毒性結膜炎治療市場的成長。例如，2018年，德國製藥公司Mundipharma Deutschland GmbH & Co. KG與義大利製藥公司NTC達成商業產品系列，獲得了在拉丁美洲獨家授權和銷售一系列眼科藥物的權利，從而擴大了其在拉丁美洲的眼科產品組合。

本次調查的主要特點

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、區域前景以及主要參與者採取的競爭策略。
• 本研究根據以下參數對全球病毒性結膜炎治療市場的主要參與者進行了分析：公司概況、財務表現、產品系列、企業發展區域、分銷策略、關鍵發展和策略以及未來計劃。
• 透過利用本報告中的見解，企業負責人和經營團隊將能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
• 這份《全球病毒性結膜炎治療市場報告》旨在為該行業內的各種相關人員提供參考，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用病毒性結膜炎治療市場分析中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 近期試飛
• 流行病學
• 併購和合作
• 監管趨勢
• 主要進展
• PEST分析

第4章 全球病毒性結膜炎治療藥物市場：依藥物類別分類，2021-2033年

• 抗生素
• 人工淚液
• 減充血劑
• 抗組織胺藥
• NSAIDs
• 抗病毒藥物
• 其他

第5章 全球病毒性結膜炎治療市場：依病毒類型分類，2021-2033年

• 腺病毒
• 腸病毒
• 其他病毒（例如單純皰疹病毒（HSV））

第6章 全球病毒性結膜炎治療藥物市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球病毒性結膜炎治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第8章 競爭情勢

• 公司簡介
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.mbH
  • NovaBay Pharmaceuticals, Inc.
  • Nicox, NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Santen Pharmaceutical Co.Ltd.
  • Alcon
  • Okogen Inc.

第9章

• 參考
• 調查方法

Viral Conjunctivitis Drugs Market is estimated to be valued at USD 394.9 Mn in 2026 and is expected to reach USD 566.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.

Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.

Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC - an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.

Key features of the study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market.

Market Segmentation

• Global Viral Conjunctivitis Drugs Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
• Artificial tears
• Decongestants
• Anti-histamines
• NSAIDS
• Anti-Viral drugs
• Steroids
• Antibiotics
• Global Viral Conjunctivitis Drugs Market, By Virus Type (Revenue, USD Mn, 2021 - 2033)
• Adenovirus
• Enterovirus
• Others
• Global Viral Conjunctivitis Drugs Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Viral Conjunctivitis Drugs Market, By Region (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • GCC Countries
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Company Profiles
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.
• Panoptes Pharma Ges.m.b.H
• NovaBay Pharmaceuticals, Inc.
• Nicox
• NanoViricides Inc.
• Novartis International AG
• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline Plc.
• Okogen Inc.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Virus Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Test Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Segment Trends
• Artificial tears
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Segment Trends
• Decongestants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Segment Trends
• Anti-histamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Segment Trends
• NSAIDS
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Segment Trends
• Anti-Viral drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 -2033, (USD Mn)
  • Segment Trends

5. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adenovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
  • Segment Trends
• Enterovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
  • Segment Trends
• Others (Herpes Simplex Virus (HSV), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
  • Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Viral Conjunctivitis Drugs Market, By Region, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2021-2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Panoptes Pharma Ges.m.b.H
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • NovaBay Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Nicox, NanoViricides Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Santen Pharmaceutical Co.Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Alcon
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Okogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact